Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 35
Submit an article Journal homepage
1,497
Views
0
CrossRef citations to date
0
Altmetric
Plain Language Summary of Publication

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study

Sara M Tolaney1 Dana-Farber Cancer Institute,Boston,MA,USACorrespondence[email protected]
View further author information
,
Shom Goel2 Sir Peter MacCallum Department of Medical Oncology,University of Melbourne,Melbourne,VIC,AustraliaView further author information
,
Adams Kusi Appiah3 Eli Lilly & Company,Indianapolis,IN,USAView further author information
,
Trish Huynh3 Eli Lilly & Company,Indianapolis,IN,USAView further author information
,
Yanyun Chen3 Eli Lilly & Company,Indianapolis,IN,USAView further author information
&
Fabrice André4 Gustave Roussy, Université Paris Saclay,INSERM,Villejuif,FranceView further author information
Pages 2341-2348 | Received 30 Jan 2023, Accepted 23 Aug 2023, Published online: 03 Oct 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.